Neuroendocrine Tumor Treatment Market To Reach $3.73 Billion By 2030

Neuroendocrine Tumor Treatment Market Growth & Trends

The global neuroendocrine tumor treatment market size is expected to reach USD 3.73 billion by 2030, according to a new report by Grand View Research, Inc. The market is estimated to register a CAGR of 6.0% from 2025 to 2030. Increasing pervasiveness of carcinoid tumors is expected to drive the market over the forecast period. Heavy investment in clinical trials by various pharmaceutical companies to develop novel products is another factor propelling the market development.

For instance, Novartis AG has the highest number of clinical trials followed by Pfizer Inc. and Ipsen Pharma. Moreover, technological advancements in therapies to treat neuroendocrine tumors are anticipated to fuel the market growth over the coming years. Some of these include PET imaging with Ga labeled Somatostatin, targeted drug therapies, and tyrosine kinase therapies. For instance, Lutathera by Novartis AG received FDA approval for the first ever radionucleotide therapy.

 Request a free sample copy or view report summary: Neuroendocrine Tumor Treatment Market Report

Neuroendocrine Tumor Treatment Market Report Highlights

• The carcinoid tumors segment dominated the market with a revenue share of 24.3% in 2024, driven by the increasing prevalence of carcinoid tumors and advancements in treatment methodologies. 

• The Somatostatin Analogs (SSAs) segment dominated the market with the largest revenue share in 2024, attributed to their proven efficacy in managing symptoms associated with neuroendocrine tumors. 

• The small intestine segment dominated the market with the largest revenue share in 2024, attributed to the higher incidence rates of neuroendocrine tumors originating from this site. 

• The hospitals segment dominated the market with the largest revenue share in 2024, driven by the comprehensive care offered by hospitals for complex cases of neuroendocrine tumors. 

• North America neuroendocrine tumor treatment market dominated the global market with a revenue share of 42.1% in 2024, driven by high healthcare expenditure coupled with advanced medical infrastructure.

Neuroendocrine Tumor Treatment Market Segmentation

Grand View Research has segmented the global neuroendocrine tumor treatment market on the basis of type, product, site, end use, and region:

Neuroendocrine Tumor Treatment Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Meningiomas

• Adrenal Cancer

• Carcinoid Tumors

• Paraganglioma

• Pheochromocytoma

• Others

Neuroendocrine Tumor Treatment Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Somatostatin Analogs (SSAs)

• Targeted Therapy

• Others

Neuroendocrine Tumor Treatment Site Outlook (Revenue, USD Billion, 2018 - 2030)

• Lung

• Pancreas

• Colon

• Small Intestine

• Rectum

• Stomach

• Others

Neuroendocrine Tumor Treatment End Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Hospitals

• Clinics

• Others

Neuroendocrine Tumor Treatment Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.       

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Norway

  • Denmark

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Singapore

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Neuroendocrine Tumor Treatment Market

• Novartis AG

• Bristol-Myers Squibb Company

• Pfizer Inc.

• Boehringer Ingelheim International GmbH

• Hutchison MediPharma Limited.

• AVEO Pharmaceuticals, Inc.

• Ipsen Pharma.

• Eli Lilly and Company.

• Exelixis, Inc.

• Jubilant Pharmova Limited